Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis

Yasui, 2005, Molecular-pathological prognostic factors of gastric cancer: a review, Gastric Cancer, 8, 86, 10.1007/s10120-005-0320-0

Real, 2003, A “catastrophic hypothesis” for pancreas cancer progression, Gastroenterology, 124, 1958, 10.1016/S0016-5085(03)00389-5

Shaheen, 2002, Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review

Neoptolemos, 2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, Lancet, 389, 1011, 10.1016/S0140-6736(16)32409-6

Goonetilleke, 2007, Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer, Eur. J. Surg. Oncol., 33, 266, 10.1016/j.ejso.2006.10.004

Capurso, 2015, Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals, World J. Gastrointest. Endosc., 7, 833, 10.4253/wjge.v7.i9.833

Poruk, 2013, Screening for pancreatic cancer: why, how, and who?, Ann. Surg., 257, 17, 10.1097/SLA.0b013e31825ffbfb

Hewitt, 2012, EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis, Gastrointest. Endosc., 75, 319, 10.1016/j.gie.2011.08.049

Alix-Panabières, 2013, Circulating tumor cells: liquid biopsy of cancer, Clin. Chem., 59, 110, 10.1373/clinchem.2012.194258

Stroun, 2001, About the possible origin and mechanism of circulating DNA: apoptosis and active DNA release, Clin. Chim. Acta, 10.1016/S0009-8981(01)00665-9

Mandel, 1948, "The nucleic acids in blood plasma in humans.", C. R. Soc. Seances Soc. Biol. Fil., 241

Metzker, 2010, Sequencing technologies—the next generation, Nat. Rev. Genet., 10.1038/nrg2626

Fleischhacker, 2007, Circulating nucleic acids (CNAs) and cancer—a survey, Biochim. Biophys. Acta Rev. Cancer, 1775, 181, 10.1016/j.bbcan.2006.10.001

Diehl, 2008, Circulating mutant DNA to assess tumor dynamics, Nat. Med., 14, 985, 10.1038/nm.1789

Marusyk, 2012, Intra-tumour heterogeneity: a looking glass for cancer?, Nat. Rev. Cancer, 12, 323, 10.1038/nrc3261

Mouliere, 2012, The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients, Expert Opin. Biol. Ther., 10.1517/14712598.2012.688023

McShane, 2005, Reporting recommendations for tumor marker prognostic studies (REMARK), J. Natl. Cancer Inst., 97, 1180, 10.1093/jnci/dji237

Theodor, 1999, Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum, Dig. Dis. Sci., 44, 2014, 10.1023/A:1026618317716

Calvez-Kelm, 2016, KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control study, Oncotarget, 7, 78827, 10.18632/oncotarget.12386

Pishvaian, 2016, A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative, Oncotarget

Pietrasz, 2016, Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker, Clin. Cancer Res.

Takai, 2016, Clinical utility of circulating tumor DNA for molecular assessment and precision medicine in pancreatic cancer, Adv. Exp. Med. Biol., 924, 13, 10.1007/978-3-319-42044-8_3

Ko, 2016, A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma, Clin. Cancer Res., 61, 10.1158/1078-0432.CCR-15-0979

Zill, 2015, Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas, Cancer Discov., 5, 1040, 10.1158/2159-8290.CD-15-0274

Hamakawa, 2015, Monitoring gastric cancer progression with circulating tumour DNA, Br. J. Cancer, 112, 352, 10.1038/bjc.2014.609

Ueda, 2016, Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence, Oncotarget, 7, 62280, 10.18632/oncotarget.11409

Luo, 2016, Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma, Biochem. Biophys. Res. Commun., 471, 596, 10.1016/j.bbrc.2016.02.011

Kukita, 2015, High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients, DNA Res., 22, 269, 10.1093/dnares/dsv010

Fang, 2016, Clinical significance of circulating plasma DNA in gastric cancer, Int. J. Cancer, 138, 2974, 10.1002/ijc.30018

Park, 2014, The quantification of HER2 and MYC gene fragments in cell-free plasma as putative biomarkers for gastric cancer diagnosis, Clin. Chem. Lab. Med., 52, 1033, 10.1515/cclm-2013-0988

Shoda, 2015, HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study, Gastric Cancer, 18, 698, 10.1007/s10120-014-0432-5

Shoda, 2016, Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer, Gastric Cancer

Andolfo, 2011, Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma, BMC Cancer, 11, 126, 10.1186/1471-2407-11-126

Komatsu, 2014, Clinical impact of predicting CCND1 amplification using plasma DNA in superficial esophageal squamous cell carcinoma, Dig. Dis. Sci., 59, 1152, 10.1007/s10620-013-3005-2

Witkiewicz, 2015, Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets, Nature Commun., 6, 10.1038/ncomms7744

Uemura, 2004, Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients, J. Gastroenterol., 56

Yamada, 1998

Maire, 2002, Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA, Br. J. Cancer, 87, 551, 10.1038/sj.bjc.6600475

Castells, 1999, K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance, J. Clin. Oncol., 578, 10.1200/JCO.1999.17.2.578

Däbritz, 2009, Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9, Pancreas, 534, 10.1097/MPA.0b013e31819f6376

Brychta, 2016, Detection of KRAS mutations in circulating tumor DNA by digital PCR in early stages of pancreatic cancer, Clin. Chem., 62, 1482, 10.1373/clinchem.2016.257469

Zambon, 2000, Co-amplification at lower denaturation-temperature PCR combined with unlabled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in plasma-circulating DNA of pancreatic adenocarcinoma cases, Clin. Chim. Acta, 35, 10.1016/S0009-8981(00)00351-X

Marchese, 2006, Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA, Pancreas, 32, 171, 10.1097/01.mpa.0000202938.63084.e3

Bettegowda, 2014, Detection of circulating tumor DNA in early- and late-stage human malignancies, Sci. Transl. Med., 6, 224ra224, 10.1126/scitranslmed.3007094

Berger, 2016, Detection of hot-spot mutations in circulating cell-free DNA from patients with intraductal papillary mucinous neoplasms of the pancreas, Gastroenterology, 10.1053/j.gastro.2016.04.034

Kinugasa, 2015, Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer, Cancer, 121, 2271, 10.1002/cncr.29364

Infante, 1990, A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas, Eur. J. Cancer, 2014, 2072

Chen, 2010, K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer, Eur. J. Surg. Oncol., 36, 657, 10.1016/j.ejso.2010.05.014

Hadano, 2016, Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer, Br. J. Cancer, 115, 59, 10.1038/bjc.2016.175

Singh, 2015, High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival, Cancer Investig., 33, 78, 10.3109/07357907.2014.1001894

Earl, 2015, Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer, BMC Cancer, 15, 797, 10.1186/s12885-015-1779-7

Tjensvoll, 2016, Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer, Mol. Oncol., 10, 635, 10.1016/j.molonc.2015.11.012

Sausen, 2015, Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients, Nat. Commun., 6, 7686, 10.1038/ncomms8686

Semrad, 2015, Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results, Int. J. Clin. Oncol., 20, 518, 10.1007/s10147-014-0730-2

Lam, 2000, Molecular biology of esophageal squamous cell carcinoma, Crit. Rev. Oncol. Hematol., 33, 71, 10.1016/S1040-8428(99)00054-2

Jiang, 1992, Amplification and expression of the human cyclin D gene in esophageal cancer, Cancer Res., 52, 2980

Jia, 2016, Discordance of somatic mutations between Asian and Caucasian patient populations with gastric cancer, Mol. Diagn. Ther., 1

Taly, 2013, Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin. Chem., 59, 1722, 10.1373/clinchem.2013.206359

Locker, 2006, ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer, J. Clin. Oncol., 24, 5313, 10.1200/JCO.2006.08.2644

Gao, 2016, Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis, Oncotarget

El Messaoudi, 2013, Circulating cell free DNA: preanalytical considerations, Clin. Chim. Acta, 424, 222, 10.1016/j.cca.2013.05.022

Siravegna, 2017, Integrating liquid biopsies into the management of cancer, Nat. Rev. Clin. Oncol., 10.1038/nrclinonc.2017.14

Dessel, 2017, Application of circulating tumor DNA in prospective clinical oncology trials–standardization of preanalytical conditions, Mol. Oncol., 11, 295, 10.1002/1878-0261.12037